Surgical Oncology Insight最新文献

{"title":"Starting a Hepato-Pancreato-Biliary surgery program from scratch: Closing the gap in West Africa","authors":"Olusegun I. Alatise ,&nbsp;Erica Mann ,&nbsp;Catherine N. Zivanov ,&nbsp;Titilayo A. Ojumu ,&nbsp;Adewale A. Aderounmu ,&nbsp;Adewale O. Adisa","doi":"10.1016/j.soi.2025.100132","DOIUrl":"10.1016/j.soi.2025.100132","url":null,"abstract":"<div><div>The burden of hepato-pancreato-biliary (HPB) disease in West Africa ranks among the highest incidence rates and poorest survival outcomes globally. In this paper, we discuss the landscape of HPB disease in West Africa and the available infrastructure to mitigate it. We describe the development of the HPB surgery program at Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC), a tertiary referral and teaching hospital in Ile-Ife, Osun State, Nigeria. We detail our case volume and describe our progressive development towards becoming the singular dedicated HPB surgery and only endoscopic retrograde cholangiopancreatography (ERCP) program in Nigeria. Our hospital’s capacity to be a leader in this way can partly be attributed to our successful partnerships with international collaborators.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100132"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Propensity score–weighted analysis of neoadjuvant therapy versus upfront surgical resection in patients with biliary tract cancers","authors":"Elsa Hallab ,&nbsp;Hanfei Qi ,&nbsp;Mark Yarchoan ,&nbsp;Christopher Shubert ,&nbsp;Jeffrey Meyer ,&nbsp;Kelly Lafaro ,&nbsp;Jin He ,&nbsp;William Burns ,&nbsp;Richard Burkhart ,&nbsp;Benjamin Philosophe ,&nbsp;Elie Ghabi ,&nbsp;Nilofer S. Azad ,&nbsp;Jane Zorzi ,&nbsp;Paige Griffith ,&nbsp;Amol Narang ,&nbsp;Ihab Kamel ,&nbsp;Kelvin Hong ,&nbsp;Christos Georgiades ,&nbsp;Robert Liddell ,&nbsp;Robert Anders ,&nbsp;Marina Baretti","doi":"10.1016/j.soi.2025.100139","DOIUrl":"10.1016/j.soi.2025.100139","url":null,"abstract":"<div><h3>Background</h3><div>Bile tract cancer (BTC) is a heterogeneous and aggressive malignancy with a poor prognosis. Surgical resection is the main potentially curative treatment, but only about 20–30 % of patients present with resectable disease. The benefit of neoadjuvant chemotherapy (NAC) in BTC remains controversial. We explored outcomes of patients with BTCs receiving NAC compared to those who underwent upfront surgical resection using a propensity score weighting approach.</div></div><div><h3>Methods</h3><div>We identified patients who underwent surgical resection for stage I-III BTC between 2019 and 2023 and were evaluated at the Johns Hopkins Liver Multidisciplinary Cancer Clinic (Liver MDC). Propensity score weighting (PSW) was used to balance groups. Groups were assessed for differences in pathological response, recurrence-free survival (RFS), and overall survival (OS). Hazard ratios (HRs) were estimated using the PSW Cox proportional hazard regression model.</div></div><div><h3>Results</h3><div>Among 56 BTC patients that fit the inclusion criteria, 34 underwent upfront surgery, and 22 received NAC. Patients receiving NAC were more likely to have higher risk disease compared to patients receiving upfront resection (77.3 % vs 23.5 %, p &lt; 0.001), including tumor size greater than 5 cm (45.5 % vs 11.8 %, p = 0.0221), lymph node involvement on staging imaging (50.0 % vs 23.5 %, p = 0.0495), and a trend towards higher mean CA19–9 at diagnosis (258.7 vs 87.7 U/mL, p = 0.179). In the univariate analysis, the NAC group showed a trend toward shorter RFS compared to the upfront surgery group (15.1 months; 95 % CI 10.3-not available (NA) versus 23.5 months; 95 % CI 15.5-NA, HR= 2.24; 95 % CI: 0.88–5.69, p = 0.082). No significant differences were seen for OS (36.5 months; 95 % CI 26.5-NA versus 48.2 months; 95 % CI 44.5-NA, HR= 1.53; 95 % CI: 0.51–4.64–5.69, p = 0.448). Following PSW multivariable Cox analyses, receipt of NAC was associated with a trend toward reduced risk of recurrence (HR 0.83; 95 % CI 0.24–2.87 p = 0.7651) and death (HR 0.66; 95 % CI 0.2–2.16 p = 0.4890), although no statistically significant differences were observed.</div></div><div><h3>Conclusion</h3><div>These findings suggest that NAC may provide benefit for patients with higher-risk BTCs, achieving outcomes comparable to upfront surgical resection. The similar pathological results between the two groups further support the potential efficacy of neoadjuvant approaches. However, prospective trials are essential to definitively establish the optimal sequencing of chemotherapy and surgery in this patient population.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100139"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143839513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival and morbidity following metastasectomy for stage IV melanoma in the era of systemic therapy: A multicenter retrospective cohort study","authors":"M.R. Jansen ,&nbsp;J.J. Bonenkamp ,&nbsp;M. Jalving ,&nbsp;L.B. Been ,&nbsp;B.L. van Leeuwen","doi":"10.1016/j.soi.2025.100138","DOIUrl":"10.1016/j.soi.2025.100138","url":null,"abstract":"<div><h3>Background</h3><div>Modern systemic therapies for stage IV melanoma often result in remarkable and durable responses. Consequently, the indications for surgical resection in stage IV melanoma patients are evolving and remain debated. This study examines the survival and morbidity following metastasectomy for stage IV melanoma in the era of systemic therapy.</div></div><div><h3>Methods</h3><div>A multicenter, retrospective cohort study was conducted at the University Medical Center Groningen and Radboud University Medical Center Nijmegen. Adult patients with stage IV (AJCC 8th) melanoma who received systemic therapy and had metastasectomy between 2010 and 2020 were included. Outcomes were overall survival (OS), progression-free survival (PFS), and morbidity following metastasectomy.</div></div><div><h3>Results</h3><div>Forty-four patients were included (median age 57 years; 54.5 % females). Twenty-five (56.8 %) patients underwent metastasectomy to achieve no evidence of disease and 19 (43.2 %) patients for symptomatic metastases. The most common procedures were small bowel segmental resections (38.6 %) and skin/soft tissue excisions (19.3 %). Postoperative complications occurred in seven (15.9 %) patients and were mostly treated conservatively. During a median follow-up of 139 months, mean OS was 92 months, and median PFS was 23 months. Patients who experienced at a least partial response to systemic treatment before metastasectomy (HR 0.24, <em>p</em> = 0.029) and had treatment from 2016 (HR 0.21, <em>p</em> = 0.004) had prolonged OS.</div></div><div><h3>Conclusions</h3><div>Metastasectomy in selected stage IV melanoma patients was associated with favorable OS, particularly in patients who had at least a partial response to systemic treatment prior to metastasectomy and had treatment from 2016. Postoperative morbidity was acceptable.</div></div><div><h3>Synopsis</h3><div>This study evaluates the survival and morbidity following metastasectomy for stage IV melanoma in the era of systemic therapy, revealing favorable outcomes, particularly in patients with at least a partial response to systemic treatment prior to surgery and who had treatment after 2016.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100138"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic and peri-hepatic cytoreductive surgery in low-grade appendiceal mucinous neoplasms","authors":"Catherine R. Lewis,&nbsp;Tamara L. Floyd,&nbsp;Casey J. Allen,&nbsp;David L. Bartlett,&nbsp;Patrick L. Wagner","doi":"10.1016/j.soi.2025.100125","DOIUrl":"10.1016/j.soi.2025.100125","url":null,"abstract":"<div><h3>Background</h3><div>Low-grade appendiceal mucinous neoplasm (LAMN) is a rare tumor that carries a risk of rupture causing pseudomyxoma peritonei (PMP). With PMP, intraperitoneal surfaces and organs become involved, including the liver capsule, porta hepatis, and peri-hepatic regions. Extensive porta hepatis and peri-hepatic involvement in PMP is often cited as a contraindication for cytoreduction. We present a retrospective review of successful cytoreductive surgery (CRS) in patients with LAMN involvement of the porta hepatis and peri-hepatic tissues.</div></div><div><h3>Methods</h3><div>A retrospective review identified patients over a 3-year period with a diagnosis of LAMN with porta hepatis and peri-hepatic involvement. Peri-operative records were reviewed for all patients who met study criteria.</div></div><div><h3>Results</h3><div>We identified 41 patients with LAMN and porta hepatis and/or peri-hepatic involvement who underwent CRS with successful debulking of these regions. Non-anatomic hepatic parenchymal resection was required in 19 patients. Median peritoneal carcinoma index was 28, and median length of stay was 13.5 days. Clavien-Dindo Grade ≥ 3 complications were seen following 36 % of cases, with no liver-specific morbidity and no peri-operative mortalities.</div></div><div><h3>Discussion</h3><div>Peri-hepatic or portal involvement by PMP can be safely addressed during CRS and should not preclude attempts at complete cytoreduction in appropriate patients who may achieve long-term disease control.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 1","pages":"Article 100125"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143183215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A single institution experience using ultrasound-guided intralesional immunotherapy in recurrent melanoma","authors":"Olivia P. Waldron ,&nbsp;Joanna T. Buchheit ,&nbsp;Colette R. Pameijer","doi":"10.1016/j.soi.2025.100130","DOIUrl":"10.1016/j.soi.2025.100130","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Intralesional therapy for recurrent melanoma is well-established for palpable lesions, however the benefit of ultrasound-guided (US) injections for non-palpable melanoma has not been well-established. This study evaluates the safety and efficacy of US-guided injection of talimogene laherparepvec (T-VEC) in the treatment of recurrent melanoma.</div></div><div><h3>Methods</h3><div>A single-institution retrospective chart review was conducted of patients who received T-VEC between 2018 and 2023. T-tests, Fisher’s exact tests and Chi-squared tests compared patient and treatment characteristics, side effects and outcomes between US-guided and non-US guided injections.</div></div><div><h3>Results</h3><div>Of 36 patients, 11 (31 %) underwent US-guided and 25 (69 %) underwent non-US-guided T-VEC injections. The most common side effects in both groups were fever and chills. The US-guided cohort had no local or systemic complications while the non-US guided group had three patients with complications. Similar response (complete or partial) rates (63.6 % US guided vs 60 % non-US guided) and progression (36.4 % US-guided vs 36 % non-US guided) occurred among the cohorts (p = 0.8). Six-month survival after starting T-VEC treatment was 72.7 % in US-guided and 76 % in non-US guided (p = 0.84).</div></div><div><h3>Conclusions</h3><div>US-guided injections for non-palpable recurrent melanoma are safe and demonstrate similar efficacy to non-US-guided injections, which increases treatment options for some patients.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 1","pages":"Article 100130"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and factors associated with heart disease in patients diagnosed with small bowel and broncho-pulmonary neuroendocrine tumors: A population-based analysis","authors":"Julie Hallet ,&nbsp;Shaheeda Ahmed ,&nbsp;Simron Singh ,&nbsp;Sten Myrehaug ,&nbsp;Wing C. Chan ,&nbsp;Anna Gombay ,&nbsp;Calvin Law","doi":"10.1016/j.soi.2024.100115","DOIUrl":"10.1016/j.soi.2024.100115","url":null,"abstract":"<div><h3>Background</h3><div>Heart disease is a complication of neuroendocrine tumors (NETs). Little is known about its occurrence in all patients diagnosed with NETs. We examined the occurrence of valvular and congestive heart disease and the use of echocardiography after NETs diagnosis.</div></div><div><h3>Methods</h3><div>We conducted a population-based retrospective cohort study of small bowel and broncho-pulmonary NETs (2000–2019). Heart disease was defined as new congestive heart failure or valvular disease. Cumulative incidence functions (CIF with 95 %CI) of heart disease and use of echocardiography were computed accounting for the competing risk of death.</div></div><div><h3>Results</h3><div>Of 5735 patients with NETs, 54.1 % had small bowel primaries and 48.8 % metastatic disease. The CIF of heart disease in all patients was 10.7 % (9.8–11.7 %) at 10 years. Heart disease was more frequent for small bowel (10-year CIF 12.7 % [11.2–14.2 %]) than broncho-pulmonary (10-year CIF 9.1 % [8.0–10.3 %]) NETs. Of 1864 patients with available urinary 5HIAA data, 64.0 % had elevated results. Heart disease was more frequent with elevated serotonin (10-year CIF 13.5 % [11.3–15.9 %]). 10-year CIF for echocardiography in all patients was 64.7 % (63.3–66.1 %), and exceeded 50 % in all sub-groups. Patterns of echocardiography CIF mirrored those of heart disease.</div></div><div><h3>Conclusions</h3><div>Valvular and congestive heart disease occurred in 10 out of 100 patients in the 10 years after small bowel and broncho-pulmonary NETs diagnosis. Patterns of echocardiography use suggest that testing is not influenced by NET disease characteristics, with risks of under-detection in at-risk individuals.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 1","pages":"Article 100115"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143183468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for early versus late venous thromboembolism after cytoreductive surgery and HIPEC","authors":"Sohini Khan ,&nbsp;Kaitlyn Kelly ,&nbsp;Jula Veerapong ,&nbsp;Andrew M. Lowy ,&nbsp;Joel M. Baumgartner","doi":"10.1016/j.soi.2024.100118","DOIUrl":"10.1016/j.soi.2024.100118","url":null,"abstract":"<div><h3>Background</h3><div>Patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) often have extensive cancer burden, long operative times, and reduced mobility postoperatively – known risk factors for venous thromboembolism (VTE). It is unknown whether risk factors differ for early versus late VTEs post-CRS-HIPEC.</div></div><div><h3>Methods</h3><div>We retrospectively studied patients undergoing CRS-HIPEC from 2007 to 2021 and analyzed VTEs occurring within 60 days of surgery. VTEs ≤ postoperative day (POD) 7 were “early”; those after POD 7 were “late”. Associated risk factors were analyzed using student’s t-test, Chi-squared test, and logistic regression.</div></div><div><h3>Results</h3><div>By POD 60, 35 of 682 CRS-HIPEC patients (5.1 %) had VTEs – eight (22.9 %) early and 27 (77.1 %) late. All early VTEs were pulmonary emboli vs. 63 % of late VTEs (p = 0.041); five (62.5 %) early VTEs were serious (Clavien-Dindo grade ≥3) vs. two (7.4 %) late VTEs (p = 0.005). Early VTEs were associated with primary ovarian cancer (37.5 % vs. 4.2 %, p &lt; 0.001), extensive pelvic dissection (87.5 % vs. 50.1 %, p = 0.035), PCI 31–39 (p = 0.002), OR time (558 vs. 420 min, p = 0.015), EBL (650 vs. 150 mL, p = 0.005), and intraoperative transfusion (62.5 % vs. 13.1 %, p = 0.002). Late VTEs were associated with higher Caprini score (9 vs. 8, p = 0.038), lower serum albumin (4.1 vs. 4.3, p = 0.002), PCI 31–39 (p = 0.012) and serious inpatient postoperative complications (22.2 % vs. 7.3 %, p = 0.008).</div></div><div><h3>Conclusions</h3><div>Severity and risk factors are markedly different for early vs. late VTEs following CRS-HIPEC. Early VTEs are more serious and associated with primary ovarian cancer and extensive cytoreduction including pelvic dissection highlighting the need for alternative prophylaxis strategies and clinical scrutiny in these populations.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 1","pages":"Article 100118"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143183471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robotic right posterior sectionectomy for biliary cystadenoma. Description of standardized approach in anatomical liver resection","authors":"Parisa Y. Kenary,&nbsp;Sharona Ross,&nbsp;Iswanto Sucandy","doi":"10.1016/j.soi.2025.100127","DOIUrl":"10.1016/j.soi.2025.100127","url":null,"abstract":"<div><h3>Objective</h3><div>With recent advances in surgical technology, minimally invasive liver resection is gradually becoming the gold-standard practice <span><span>1</span></span>, <span><span>2</span></span>, <span><span>4</span></span>. Biliary cystadenoma is a rare tumor with malignant potential, therefore parenchymal-sparing liver resection is the preferred approach <span><span>3</span></span>, <span><span>4</span></span>. Due to its technical challenge, laparoscopic or robotic anatomical right posterior sectionectomy are infrequently performed in daily practice and rarely described in multimedia literatures. Herein, we describe our standardized technique for robotic right posterior sectionectomy.</div></div><div><h3>Methods</h3><div>A 65-year-old woman presented with a complex 5.3 cm multiloculated liver cyst involving segment 6/7. CT scan and MRI revealed multiple enhancing solid mural nodules and thickened septum concerning for neoplasm. Right posterior sectoral portal vein and hepatic artery were ligated to establish inflow control. After an adequate liver mobilization and dissection of hepatocaval confluence, the line of the parenchymal transection was drawn toward the root of the right hepatic vein following a demarcation line. Mapping of the middle and right hepatic veins was undertaken using ultrasonic guidance. Parenchymal division was undertaken under intermittent Pringle maneuver as necessary. The operation was completed with transection of the right hepatic vein using a robotic stapler.</div></div><div><h3>Results</h3><div>The operative time of 5 hours with minimal blood loss. The postoperative course was uneventful. A final pathology report confirmed a 6 cm multiloculated biliary cystadenoma without evidence of invasive carcinoma.</div></div><div><h3>Conclusion</h3><div>Robotic right posterior sectionectomy is technically demanding, however feasible, safe, and reproducible. We believe this technique can provide an alternative method to the conventional open operation for segment 6/7 liver tumor resection.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 1","pages":"Article 100127"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143183218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma","authors":"David G. Su ,&nbsp;Madeline McNamara ,&nbsp;Margaret A. Kaszycki ,&nbsp;Alexander E. Frey ,&nbsp;Jeffrey J. Ishizuka ,&nbsp;Philippos A. Costa ,&nbsp;Thuy T. Tran ,&nbsp;Harriet M. Kluger ,&nbsp;James E. Clune ,&nbsp;Sarah A. Weiss ,&nbsp;Kelly L. Olino","doi":"10.1016/j.soi.2024.100120","DOIUrl":"10.1016/j.soi.2024.100120","url":null,"abstract":"<div><h3>Background and Objectives</h3><div>Talimogene laherparepvec (T-VEC) is an intralesional cancer immunotherapy in patients with unresectable stage IIIB-IV melanoma and Merkel cell carcinoma (MCC). This study assesses T-VEC outcomes in patients with in-transit melanoma and MCC refractory to anti-PD-1 blockade.</div></div><div><h3>Methods</h3><div>All patients with advanced melanoma or MCC with ≥ 1 measurable lesion(s) were retrospectively evaluated from 2019 to 2023. Only those who received ICI therapy for ≥ 3 months with progression of regional metastasis prior to receiving T-VEC were included. Clinicopathologic and treatment data were reviewed.</div></div><div><h3>Results</h3><div>Seventeen patients underwent T-VEC therapy, consisting of thirteen melanoma and four MCC cases. Median age was 75.9 and 79.6 for melanoma and MCC cases respectively. Eleven melanoma (84 %) and three MCC (75 %) cases received extremity injections. Median number of in-transit metastatic sites for melanoma and MCC were 4 and 10; respectively, and the median number of treatment cycles per patient was five in both groups. Ten total patients responded with 8 complete responses and 2 partial responses, while five (4 melanoma; 1 MCC) had disease progression. Of seventeen patients, two discontinued T-VEC due to grade 3 + adverse events.</div></div><div><h3>Conclusion</h3><div>T-VEC following or in conjunction with immunotherapy exhibits tolerability and potential benefit in patients with advanced MCC and melanoma.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 1","pages":"Article 100120"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143183472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Society of surgical oncology medical student & trainee primer for breast surgical oncology","authors":"Marissa K. Boyle ,&nbsp;Julia M. Selfridge ,&nbsp;Rachel E. Sargent ,&nbsp;Y. Everett Warren Jr ,&nbsp;Julia M. Chandler ,&nbsp;Christopher P. Childers ,&nbsp;Breast Specialty Members, 2024-2025 SSO Fellows and Young Attendings Committee","doi":"10.1016/j.soi.2025.100129","DOIUrl":"10.1016/j.soi.2025.100129","url":null,"abstract":"<div><div>The goal of this primer is to educate the future generation of surgeons and prepare trainees for their clinical rotations in the operating room and with patient care. This primer will introduce medical students and trainees to the management of benign breast disease and breast cancer for their clinical breast surgical oncology rotation. More comprehensive management of patients and the knowledge required to do so will stem from the most recent clinical trials and advances in the field, which is ever evolving.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 1","pages":"Article 100129"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143430051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}